Cagrilintide
Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Who's worth your money for Cagrilintide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 23 scored sellers
$56.99 · 10mg · 99.9% purity
Most tested
17 independent COAs on file
$335 · 10mg · 99.7% purity
Average price
$12.57/mg
Sellers
47
45-day trend
-7.9%
34 of 47 sellers have a current price· 6 stale hidden· 5 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 10h ago
$5.70/mg -54.7% vs avg$56.99
10mg
- 🇺🇸 Peptide Partners99
✓ verified at source · 9h ago
$33.50/mg +166.4% vs avg$335
10mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 10h ago
$8.30/mg -34% vs avg$83.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 10h ago
$10.00/mg -20.5% vs avg$99.99
10mg
- 🇺🇸 Sunrise Bioresearch94
via Disclosed Labs · 10h ago
$4.70/mg -62.6% vs avg$235
50mg
- 🇺🇸 Forge Performance Co.94
✓ verified at source · 9h ago
$6.65/mg -47.1% vs avg$66.50
10mg
- 🇺🇸 Peptide Crafters94
✓ verified at source · 10h ago
$13.00/mg +3.4% vs avg$65.00
5mg
- 🇺🇸 Polaris Peptides90
via Disclosed Labs · 10h ago
$14.00/mg +11.3% vs avg$140
10mg
- 🇺🇸 Peptide Plugs89
✓ verified at source · 1d ago
$6.00/mg -52.3% vs avg$60.00
10mg
- 🇺🇸 Soma Peptides89
✓ verified at source · 1d ago
$12.40/mg -1.4% vs avg$124
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Cagrilintide
Get one email when the market actually moves — no newsletter, no noise.
About Cagrilintide
CAS
1415456-99-3
Molecular formula
C194H312N54O59S2
Sequence
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
Typical dose range
0.3–4.5 mg once weekly subcutaneous (Phase 2); 2.4 mg/week maintenance in Phase 3 REDEFINE/REIMAGINE trials
Half-life
~159–195 hours (~7–8 days)
COAs for Cagrilintide
144 third-party tests across 35 vendors. Each card links to the full report.
For
Cagrilintide
by Sunrise Bioresearch· batch 6WSEGN4
For
Cagrilintide
by Peptide Plugs· batch 103-11-ZB
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-2608
For
Cagrilintide
by EZ Peptides· batch EZP-CAG1006162026-02
For
Cagrilintide
by Ion Peptide· batch CGL5-06172026
For
Cagrilintide 10
by EZ Peptides· batch EZP-CAG10061620226-02
For
Cagrilintide
by Ion Peptide· batch CGL10-06252026
For
Cagrilintide
by Ion Peptide· batch CGL5-06242026
For
Cagrilintide
by Optima Supply· batch OS-2026-2806
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-3852
For
Cagrilintide
by Peptide Supply Co.· batch CGL10 06032026
For
Cagrilintide
by Soma Peptides· batch CAX0052658
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide 5mg
by EZ Peptides· batch EZP-CAG05051520226-12
For
Cagrilintide
by Nox Amino· batch NA-CG0526-01
For
Cagrilintide
by Peptide Partners· batch SPL-3792
For
Cagrilintide
by NG Peptide· batch CG10-12
For
Cagrilintide
by NG Peptide· batch CG05-08
For
Cagrilintide
by Modern Research Peptides· batch RHKC6242
For
Cagrilintide
by Crush Research· batch CRCAG-5-2604-1
For
Cagrilintide
by Peptide Partners· batch CG202603
For
Cagrilintide
by Qihang Peptide· batch 4
For
Cagrilintide
by Amino Club· batch CAG0001
20 citations indexed for Cagrilintide
review · 2026
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
Study · 2026
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Background Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
rct · 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
rct · 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.
rct · 2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.